Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/DIP2B_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/DIP2B_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/DIP2B_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/DIP2B_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/DIP2B_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/DIP2B_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/DIP2B_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/DIP2B_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/DIP2B_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/DIP2B_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:006056015 | Oral cavity | EOLP | developmental growth involved in morphogenesis | 41/2218 | 234/18723 | 6.54e-03 | 3.21e-02 | 41 |
GO:003030812 | Oral cavity | EOLP | negative regulation of cell growth | 34/2218 | 188/18723 | 7.73e-03 | 3.69e-02 | 34 |
GO:000740910 | Oral cavity | EOLP | axonogenesis | 66/2218 | 418/18723 | 8.99e-03 | 4.13e-02 | 66 |
GO:003134521 | Oral cavity | EOLP | negative regulation of cell projection organization | 33/2218 | 186/18723 | 1.14e-02 | 4.99e-02 | 33 |
GO:006156414 | Oral cavity | EOLP | axon development | 72/2218 | 467/18723 | 1.14e-02 | 5.00e-02 | 72 |
GO:001604931 | Oral cavity | NEOLP | cell growth | 90/2005 | 482/18723 | 9.23e-08 | 3.43e-06 | 90 |
GO:003253532 | Oral cavity | NEOLP | regulation of cellular component size | 73/2005 | 383/18723 | 6.70e-07 | 1.93e-05 | 73 |
GO:000155831 | Oral cavity | NEOLP | regulation of cell growth | 73/2005 | 414/18723 | 1.23e-05 | 2.23e-04 | 73 |
GO:001097521 | Oral cavity | NEOLP | regulation of neuron projection development | 77/2005 | 445/18723 | 1.44e-05 | 2.53e-04 | 77 |
GO:004867521 | Oral cavity | NEOLP | axon extension | 29/2005 | 120/18723 | 1.97e-05 | 3.29e-04 | 29 |
GO:006156421 | Oral cavity | NEOLP | axon development | 78/2005 | 467/18723 | 4.49e-05 | 6.26e-04 | 78 |
GO:000740914 | Oral cavity | NEOLP | axonogenesis | 71/2005 | 418/18723 | 5.64e-05 | 7.62e-04 | 71 |
GO:001820531 | Oral cavity | NEOLP | peptidyl-lysine modification | 64/2005 | 376/18723 | 1.21e-04 | 1.43e-03 | 64 |
GO:005076721 | Oral cavity | NEOLP | regulation of neurogenesis | 62/2005 | 364/18723 | 1.50e-04 | 1.71e-03 | 62 |
GO:004592621 | Oral cavity | NEOLP | negative regulation of growth | 46/2005 | 249/18723 | 1.58e-04 | 1.77e-03 | 46 |
GO:006056022 | Oral cavity | NEOLP | developmental growth involved in morphogenesis | 43/2005 | 234/18723 | 2.87e-04 | 2.86e-03 | 43 |
GO:199013822 | Oral cavity | NEOLP | neuron projection extension | 34/2005 | 172/18723 | 3.02e-04 | 2.98e-03 | 34 |
GO:003030821 | Oral cavity | NEOLP | negative regulation of cell growth | 36/2005 | 188/18723 | 3.88e-04 | 3.63e-03 | 36 |
GO:004858822 | Oral cavity | NEOLP | developmental cell growth | 41/2005 | 234/18723 | 1.05e-03 | 8.00e-03 | 41 |
GO:005196012 | Oral cavity | NEOLP | regulation of nervous system development | 68/2005 | 443/18723 | 1.46e-03 | 1.03e-02 | 68 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DIP2B | SNV | Missense_Mutation | | c.3997N>A | p.Asp1333Asn | p.D1333N | Q9P265 | protein_coding | deleterious(0.03) | probably_damaging(1) | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
DIP2B | SNV | Missense_Mutation | | c.4606G>C | p.Val1536Leu | p.V1536L | Q9P265 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A8-A09C-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DIP2B | SNV | Missense_Mutation | | c.2437N>T | p.Asp813Tyr | p.D813Y | Q9P265 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
DIP2B | SNV | Missense_Mutation | | c.4702N>C | p.Asp1568His | p.D1568H | Q9P265 | protein_coding | tolerated(0.07) | probably_damaging(0.996) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
DIP2B | SNV | Missense_Mutation | novel | c.3082A>G | p.Lys1028Glu | p.K1028E | Q9P265 | protein_coding | deleterious(0.02) | probably_damaging(0.947) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DIP2B | SNV | Missense_Mutation | | c.4214A>C | p.Tyr1405Ser | p.Y1405S | Q9P265 | protein_coding | deleterious(0.01) | possibly_damaging(0.906) | TCGA-AO-A12H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
DIP2B | SNV | Missense_Mutation | novel | c.1694N>T | p.Ala565Val | p.A565V | Q9P265 | protein_coding | tolerated(1) | benign(0.052) | TCGA-BH-A5IZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
DIP2B | SNV | Missense_Mutation | | c.2918N>T | p.Gly973Val | p.G973V | Q9P265 | protein_coding | deleterious(0) | probably_damaging(0.932) | TCGA-D8-A1XY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | tamoxiphen | SD |
DIP2B | SNV | Missense_Mutation | | c.4058A>G | p.Glu1353Gly | p.E1353G | Q9P265 | protein_coding | tolerated(0.07) | probably_damaging(1) | TCGA-E2-A10A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | zoladex | SD |
DIP2B | SNV | Missense_Mutation | | c.2799N>C | p.Met933Ile | p.M933I | Q9P265 | protein_coding | deleterious(0.01) | benign(0.08) | TCGA-E9-A295-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |